The first meeting of the Pharmaceutical Commission of the Iran–India Joint Chamber of Commerce was held at the proposal of Golrang Pharmaceutical Investment co.(GPI co.).
According to the Public Relations department of GPI co., the inaugural meeting of the specialized Pharmaceutical Commission of the Iran–India Joint Chamber of Commerce was held on Sunday, January 4, 2026 (15 Dey 1404), following a proposal by GPI co. and with the participation of a number of pharmaceutical industry stakeholders and representatives.
The meeting was attended by Mr. Jamili, President of the Iran–India Joint Chamber of Commerce; Mr. Abdeh‑Zadeh, President of the Iranian Syndicate of Human Pharmaceutical Producers; Ms. Haleh Hosseinzadeh, representative of Bank Saman; and representatives of member pharmaceutical companies.
From Golrang Pharmaceutical Investment Group, Mr. Mortazavi, CEO of Faran Shimi; Mr. Akbari, CEO of Hasti Arya Shimi; Ms. Behnoosh Salehi, CEO of Soroush Mana Pharmed; and Ms. Sheida Mahnam, International Advisor to the Holding, shared their views and perspectives during the session.
During the meeting, participants emphasized that one of the fundamental challenges facing Iran’s pharmaceutical industry in its engagement with India is the absence of a formal, transparent, and institutionalized platform for structured cooperation. This issue, beyond challenges related to raw material supply and currency transfer, has significantly affected the formation of sustainable and long‑term collaborations.
The establishment of the Pharmaceutical Commission of the Iran–India Joint Chamber of Commerce, given India’s position as a global player in the pharmaceutical industry, has been pursued with objectives including the creation of a platform for long‑term interactions, facilitation of joint business processes, organization of the participation of pharmaceutical companies from both countries in specialized exhibitions, facilitation of group visa issuance and organization of specialized tours, as well as the establishment of formal links with Indian pharmaceutical institutions such as IDMA and Pharmexcil.
In addition, missions such as creating infrastructure for technology transfer, supporting joint investment opportunities, backing commercial negotiations, and facilitating business‑to‑business (B2B) interactions between Iranian and Indian pharmaceutical companies have been defined for this commission.
During the continuation of the meeting, representatives of the participating pharmaceutical companies introduced their fields of activity, outlined their cooperation priorities with India, and shared their perspectives on opportunities and challenges in the pharmaceutical markets of the two countries, while also proposing suggestions for the future direction of the commission’s activities.
At the conclusion of the meeting, decisions were made regarding the timeline and key focus areas of future sessions, and emphasis was placed on the continuity of cooperation and active participation of members.
The Pharmaceutical Commission of the Iran–India Joint Chamber of Commerce is expected to play an effective role in expanding pharmaceutical cooperation between the two countries by establishing a formal and institutional communication channel.
